Alnylam Pharmaceuticals (ALNY) total liabilities
Alnylam Pharmaceuticals (ALNY) had total liabilities of $4.18B at the end of fiscal 2025 (December 31, 2025). That is 0.1% higher than the $4.17B of fiscal 2024. Figures as of 19 Nov 2026, 02:33 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total liabilities, fiscal 2025
- $4.18B
- Change on fiscal 2024
- +0.1%
- Growth, 5 years
- +11.8% a year
- Growth, 10 years
- +42.4% a year
- Highest on record
- $4.18Bfiscal 2025
- Lowest on record
- $121.80Mfiscal 2015
- Fiscal years on record
- 172009–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Alnylam Pharmaceuticals total liabilities, in more detail
Over the five fiscal years to 2025 total liabilities grew at a compound 11.8% a year; over ten years the rate was 42.4% a year. Across the 17 fiscal years on record (2009–2025), the highest was $4.18B in fiscal 2025 and the lowest $121.80M in fiscal 2015.
Total liabilities by fiscal year
Alnylam Pharmaceuticals total liabilities, year by year
| Fiscal year | Total liabilities | Change | Year ended |
|---|---|---|---|
| 2025 | $4.18B | 0.1% up | |
| 2024 | $4.17B | 3.0% up | |
| 2023 | $4.05B | 9.3% up | |
| 2022 | $3.70B | 21.3% up | |
| 2021 | $3.06B | 27.8% up | |
| 2020 | $2.39B | 150.0% up | |
| 2019 | $956.44M | 250.6% up | |
| 2018 | $272.84M | 19.5% up | |
| 2017 | $228.30M | 33.4% down | |
| 2016 | $342.59M | 181.3% up | |
| 2015 | $121.80M | 15.0% down | |
| 2014 | $143.33M | 4.6% down | |
| 2013 | $150.18M | 2.1% down | |
| 2012 | $153.47M | 6.4% down | |
| 2011 | $163.92M | 30.3% down | |
| 2010 | $235.03M | 22.5% down | |
| 2009 | $303.42M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.
How to read it
It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.
Total liabilities at health care companies of similar size
| Company | Total liabilities | Fiscal year |
|---|---|---|
| Tenet Healthcare THC | $20.70B | 2025 |
| BioNTech BNTX | €2.76B | 2025 |
| Guardant Health GH | $2.11B | 2025 |
| Alnylam Pharmaceuticals ALNY | $4.18B | 2025 |
| Zimmer Biomet Holdings ZBH | $10.39B | 2025 |
| Medpace Holdings MEDP | $1.52B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Alnylam Pharmaceuticals, figure by figure
- Alnylam Pharmaceuticals market cap
- Alnylam Pharmaceuticals revenue
- Alnylam Pharmaceuticals earnings
- Alnylam Pharmaceuticals earnings per share (EPS)
- Alnylam Pharmaceuticals P/E ratio
- Alnylam Pharmaceuticals P/S ratio
- Alnylam Pharmaceuticals P/B ratio
- Alnylam Pharmaceuticals free cash flow
- Alnylam Pharmaceuticals operating margin
- Alnylam Pharmaceuticals dividend
- Alnylam Pharmaceuticals shares outstanding
- Alnylam Pharmaceuticals total debt
- Alnylam Pharmaceuticals cash on hand
- Alnylam Pharmaceuticals total assets
- Alnylam Pharmaceuticals net assets (shareholders' equity)
- Alnylam Pharmaceuticals return on equity (ROE)
- Alnylam Pharmaceuticals return on invested capital (ROIC)
Alnylam Pharmaceuticals (ALNY) overview: price, valuation and scorecardAll health care companies by market value
Alnylam Pharmaceuticals total liabilities: questions and answers
How large are Alnylam Pharmaceuticals's total liabilities?
Alnylam Pharmaceuticals (ALNY) had total liabilities of $4.18B at the end of fiscal 2025 (December 31, 2025). That is 0.1% higher than the $4.17B of fiscal 2024.
What is the growth rate of Alnylam Pharmaceuticals's total liabilities?
Over the five fiscal years to 2025 total liabilities grew at a compound 11.8% a year; over ten years the rate was 42.4% a year.
What are the highest and lowest total liabilities figures on record for Alnylam Pharmaceuticals?
Across the 17 fiscal years on record (2009–2025), the highest was $4.18B in fiscal 2025 and the lowest $121.80M in fiscal 2015.
How is Alnylam Pharmaceuticals's total liabilities calculated?
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Alnylam Pharmaceuticals it is on record here for 17 fiscal years, 2009 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: total liabilities
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Alnylam Pharmaceuticals (ALNY) total liabilities”, data as of 19 November 2026. https://funkfolio.com/stock/ALNY/total-liabilities
Underlying data: the company's filings with the SEC and Yahoo Finance.